UNSPSC 51283954: Vanyldisulfamide

This classification denotes a sulfonamide anti-infective agent with the molecular formula C20H22N4O6S2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 541ZDL2E7U, chemically known as n4,n4-vanillyldenebis(sulfanilamide) but more generally known as vanyldisulfamide, which bears U.S. National Institutes of Health Compound Identifier 216267. The European Medicines Agency schedules Vanyldisulfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00024MIG.

The term VANYLDISULFAMIDE is an International Non-Proprietary Name. VANYLDISULFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(N)C1CCC(NC(NC2CCC(S(=O)(=O)N)CC2)C2CC(OC)C(O)CC2)CC1.

UNSPSC 51283954 Vanyldisulfamide, a Commodity code, shows little relevant recent activity aligned with its nominal scope. The recent opportunities tagged under this code—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for fire rescue, and generic multi-source pharmaceuticals through cooperative purchasing—address pharmaceutical and medical supply procurement broadly but do not reflect purchases of vanyldisulfamide as a discrete chemical or pharmaceutical ingredient. The mismatch between the code's chemical specificity and the actual work being solicited suggests either categorization error in the source data or that vanyldisulfamide itself is not a current procurement focus among state and local governments. State and local buying under this code, to the extent it occurs, would target pharmaceutical manufacturers and medical supply vendors capable of delivering regulated chemical ingredients or finished pharmaceutical products, but the recent solicitation record does not demonstrate active demand for vanyldisulfamide in particular.

The issuing bodies in the recent opportunities include Seminole County, Florida (IFB for naloxone and drug deactivation systems, due July 26, 2023); the Texas Health and Human Services Commission (RFI for direct-to-manufacturer prescription programs, posted April 3, 2026); the City of Tampa (IFB for medical and first aid supplies with an estimated contract value of $700,000.00, due March 13, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local jurisdictions (RFP for generic pharmaceuticals and OTC products, due March 26, 2026). Geographic activity spans Florida, Texas, Minnesota, and Oregon through cooperative purchasing, but these opportunities do not demonstrate a sustained market for vanyldisulfamide. Business development professionals should monitor whether future solicitations under this code reflect actual chemical-ingredient or specialized-pharmaceutical demand, or whether recategorization occurs.